Skip to content

Pulmonary vein isolation or atrioventricular node ablation in patients with heart failure and symptomatic atrial fibrillation diminishing CRT response (PULVERISE-AF-CRT): A randomized study

Pulmonary vein isolation or atrioventricular node ablation in patients with heart failure and symptomatic atrial fibrillation diminishing CRT response (PULVERISE-AF-CRT): A randomized study - PVI vs AVN ablation: PULVERISE-AF-CRT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON52003
Enrollment
100
Registered
2022-05-09
Start date
2021-05-01
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation heartfailure

Interventions

all patients will undergo either PVI or atrioventricular node ablation.

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Presence of a cardiac resynchronization therapy device (CRT-D or CRT-P) and optimal medical therapy according to current guidelines. • Patients with paroxysmal or persistent AF, having AF or HF related symptoms. • Patient with paroxysmal AF should have >25% burden or inadequate biventricular pacing (= 18 years

Exclusion criteria

Exclusion criteria: • Documented left atrial diameter > 6 cm (parasternal long axis). • Longstanding persistent AF longer than 2 years. • Contraindication to chronic anticoagulation therapy or heparin • Previous left heart ablation procedure for AF • Acute coronary syndrome, cardiac surgery, angioplasty or stroke within 2 months prior to enrolment • Untreated hypothyroidism or hyperthyroidism • Enrolment in another investigational drug or device study. • Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age. • Mental or physical inability to participate in the study. • Listed for heart transplant. • Cardiac assist device implanted. • Planned cardiovascular intervention. • Life expectancy

Design outcomes

Primary

MeasureTime frame
The primary end point is defined as the hierarchical occurrence of all-cause death, cardiovascular hospitalization (heart failure or stroke), and the change in quality of life at 1 year.

Secondary

MeasureTime frame
Death from any cause, unplanned hospitalization related to heart failure, death from cardiovascular disease, cerebrovascular accident, unplanned hospitalization for cardiovascular disease, and any hospitalization. Furthermore changes in the Kansas city cardiomyopathy questionnaire were assessed. Also procedure related adverse events and atrial fibrillation-free intervals were assessed.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)